A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

ICOS Corporation

Overview

The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Pneumonia Sepsis

Interventions

Recombinant Chimeric Monoclonal AntibodyDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Current diagnosis of community-acquired pneumonia. * Evidence of systemic inflammatory response to infection. Exclusion Criteria: * Atypical or viral pneumonia based on clinical or epidemiologic suspicion by the investigator. * Presence of organ failure.

Locations (1)

ICOS Corporation

Bothell, Washington, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.